Загрузка...
Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
BACKGROUND. The use of immunotherapeutic agents, specifically immune checkpoint inhibitors (ICIs) for solid malignancies, is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) com...
Сохранить в:
| Опубликовано в: : | Ann Surg Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7594106/ https://ncbi.nlm.nih.gov/pubmed/31965370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08183-0 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|